Dr. David L. Kilpatrick, MD

Dr. Kilpatrick practices at Louisiana Retina a Professional Medical Corporation in Denham Springs, Louisiana.

Dr. Kilpatrick's NPI, 1225449317, was assigned on May 12, 2014. Dr. Kilpatrick graduated from Louisiana State University School of Medicine in New Orleans in 2014. Dr. Kilpatrick holds Louisiana license 330501.

Dr. Kilpatrick's primary practice is Louisiana Retina a Professional Medical Corporation, at 303 Veterans Blvd, Denham Springs, LA 70726 in Livingston Parish. The practice phone is (225) 242-9729.

Dr. Kilpatrick's primary practice is Louisiana Retina a Professional Medical Corporation in Denham Springs, Louisiana. Dr. Kilpatrick is also affiliated with Our Lady of the Lake Regional Medical Center. The medical group on file is LSU Healthcare Network. Dmand AI also links Dr. Kilpatrick to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kilpatrick practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Kilpatrick's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dmand AI has Dr. Kilpatrick's licenses on file in 2 states: Louisiana and Mississippi.

CMS data shows 9,167 Medicare services from Dr. Kilpatrick across 10 procedure codes in 2024, for 361 Medicare patients. Medicare paid $476,497 for them. Every service was in an office.

CMS counts 361 Medicare patients who saw Dr. Kilpatrick in 2024. The largest group is 65 to 74, with 170 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kilpatrick's median patient age at 71, with 58% women.

In 2024, Dr. Kilpatrick wrote 642 Medicare Part D claims for 204 patients. 56% of them were for generic drugs. CMS names the drug for 576 of them, across 10 drugs with 11 or more claims each, at $22,684 in total drug cost. In 2023, CMS named 426 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Kilpatrick for performance year 2024, reported as part of a group. Dr. Kilpatrick accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Kilpatrick in 2020. 2020 was the busiest year, with 2. Dr. Kilpatrick's most frequent co-authors are Christine Curcio, DO, Benjamin Echols, MD and Brian Christopher Samuels, MD, PhD.

CMS Open Payments shows 115 general payments to Dr. Kilpatrick from 24 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 97% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $784.

Dr. Kilpatrick graduated from Louisiana State University School of Medicine in New Orleans in 2014.